Mycelx Technologies H1 revenue rises on paid trials, equipment leases
Reuters2026/07/30 06:29
Overview
US water treatment tech firm's H1 2026 revenue rose to $2.1 mln from $1.7 mln yr/yr
Company expects stronger H2 as $3.9 mln Permian Basin project revenue recognized in Q3
Management says FY2026 revenue on track, with 80% of forecast already booked or recurring
Outlook
MYCELX expects FY2026 revenue of $11.0 mln, with 80% already booked or contracted
Company sees stronger H2 performance as major projects progress and recurring revenue increases
MYCELX says final 2026 revenue depends on project delivery timelines and potential new wins
Result Drivers
RECURRING SALES - Paid trials, equipment leases, and recurring media sales were main contributors to H1 revenue growth
OFFSHORE PROJECTS - Additional offshore work in the Gulf of Mexico and accelerated filter media sales supported recurring revenue
PIPELINE EXPANSION - Company built largest opportunity pipeline in its history, spanning produced water and PFAS treatment projects
Company press release: ID:nRSd4493Oa
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
H1 Revenue |
|
$2.10 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the environmental services equipment peer group is "buy."
Wall Street's median 12-month price target for MYCELX Technologies Corp is GBp86.00, about 53.6% above its July 29 closing price of GBp56.00
The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 109 three months ago
Reuters Recommended Reads
July 28 - Xylem raises annual profit forecast as AI growth lifts demand for water-treatment equipment
July 28 - Veralto Q2 results beat estimates on industrial water treatment demand; raises outlook
July 28 - NOV Inc Q2 revenue beats estimates, helped by offshore project strength
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
NewAmsterdam Pharma appoints Robert Gunning principal accounting officer
Byrna Technologies director Rose P. Keravuori files initial beneficial ownership statement
Real Matters posts transcript of Q3 2026 earnings conference call